Senzar Asset Management Llc Trimmed Aerie Pharmaceuticals Inc (NASDAQ:AERI) Position by $11.22 Million

May 17, 2018 - By Nicole Mills

Big Money Sentiment decreased to 1.2 in 2017 Q4. It has change of 0.53, from 2017Q3’s 1.73. The ratio fall due to AERI positioning: 23 sold and 48 reduced. 21 funds amassed holdings and 64 increased holdings. Investors holded 34.42 million in 2017Q3 but now own 34.86 million shares or 1.29% more. Bnp Paribas Arbitrage invested in 0% or 6,926 shs. Federated Investors Pa stated it has 9,537 shs or 0% of all its holdings. Alliancebernstein Limited Partnership invested 0.02% of its capital in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Tower Rech Ltd Liability Corporation (Trc) reported 0% stake. Kazazian Asset Management Limited Liability invested 0.76% of its capital in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Pub Employees Retirement Association Of Colorado holds 2,940 shs or 0% of its capital. Barclays Public Ltd invested in 0% or 8,805 shs. American Interest Grp Inc Inc reported 22,322 shs or 0% of all its holdings. Platinum Inv Mngmt Ltd accumulated 37,600 shs. Parkside Bank & Trust owns 0.01% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 229 shs. Dekabank Deutsche Girozentrale holds 15,900 shs or 0.01% of its capital. Moreover, Atwood And Palmer has 0% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 200 shs. Waddell And Reed Finance Inc reported 455,427 shs. Price T Rowe Associates Inc Md reported 0% of its capital in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). First Mercantile Trust Communication holds 0.08% or 6,787 shs in its capital.

Senzar Asset Management Llc’s holdings in Aerie Pharmaceuticals Inc (NASDAQ:AERI) is reduced by 74.62% based on its latest 2018Q1 regulatory filing with the SEC. The company’s stock Sank 12.77% while Senzar Asset Management Llc sold 207,732 shares. The health care company announced $3.83M value for the 2018Q1. Now the hedge fund is holding 70,668 shares, compared to the 278,400 from the previous quarter. $2.02 billion is Aerie Pharmaceuticals Inc’s MC. AERI touched $51.2 during the last trading session after $0.8 change.Currently Aerie Pharmaceuticals, Inc. is uptrending after 16.25% change in last May 17, 2017. AERI has 224,990 shares volume. AERI outperformed the S&P 500 by 4.70%.

Senzar Asset Management Llc has risen its stake in and also increased its holding in by shares in the quarter, for a total of shares.

Senzar Asset Management Llc is a New York-based hedge fund with more than $442.00 million AUM in December, 2014. Taken from Senzar Asset Management latest Adv, the fund reported to have 7 full and part-time employees. Among which 4 performing investment advisory and research functions. The hedge fund had between 1-10 clients.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Coverage

In total 6 analysts cover Aerie Pharma (NASDAQ:AERI). “Buy” rating has 6, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 11 are the (NASDAQ:AERI)’s analyst reports since December 18, 2017 according to StockzIntelligence Inc. The company rating was maintained by Canaccord Genuity on Wednesday, January 24. On Friday, February 16 the company was reinitiated by H.C. Wainwright. On Wednesday, May 9 the company was maintained by Mizuho. On Wednesday, May 9 the company was maintained by H.C. Wainwright. On Tuesday, January 2 the rating was maintained by Stifel Nicolaus with “Buy”. On Thursday, March 29 the firm has “Buy” rating given by Mizuho. On Wednesday, February 28 the rating was maintained by Cantor Fitzgerald with “Buy”. On Thursday, March 1 the stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) earned “Buy” rating by H.C. Wainwright. On Tuesday, May 8 the firm has “Buy” rating given by Cantor Fitzgerald. On Monday, December 18 the rating was maintained by Cantor Fitzgerald with “Buy”.

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases.The firm is worth $2.02 billion. The Company’s lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension.Currently it has negative earnings. The firm is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: